{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T17:41:06Z","timestamp":1760204466470},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,11,27]],"date-time":"2010-11-27T00:00:00Z","timestamp":1290816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s00277-010-1125-8","type":"journal-article","created":{"date-parts":[[2010,11,26]],"date-time":"2010-11-26T07:03:11Z","timestamp":1290754991000},"page":"709-717","source":"Crossref","is-referenced-by-count":28,"title":["The prognostic significance of TP53 mutations in Chinese patients with chronic lymphocytic leukemia is independent of del(17p13)"],"prefix":"10.1007","volume":"90","author":[{"given":"Hua-Jie","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Tao","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan-Xia","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Mei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-Yuan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kou-Rong","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian-Yong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,11,27]]},"reference":[{"key":"1125_CR1","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.leukres.2007.10.009","volume":"32","author":"W Xu","year":"2008","unstructured":"Xu W, Li JY, Wu YJ et al (2008) Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. Leuk Res 32:1071\u20131077","journal-title":"Leuk Res"},{"key":"1125_CR2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1056\/NEJMra041720","volume":"352","author":"N Chiorazzi","year":"2005","unstructured":"Chiorazzi N, Rai KR, Ferrarini M (2005) Chronic lymphocytic leukemia. N Engl J Med 352:804\u2013815","journal-title":"N Engl J Med"},{"key":"1125_CR3","first-page":"400","volume":"55","author":"A Berkova","year":"2008","unstructured":"Berkova A, Pavlistova L, Babicka L et al (2008) Combined molecular biological and molecular cytogenetic analysis of genomic changes in 146 patients with B-cell chronic lymphocytic leukemia. Neoplasma 55:400\u2013408","journal-title":"Neoplasma"},{"key":"1125_CR4","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1182\/blood-2001-11-0066","volume":"100","author":"K Lin","year":"2002","unstructured":"Lin K, Sherrington PD, Dennis M et al (2002) Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 100:1404\u20131409","journal-title":"Blood"},{"key":"1125_CR5","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood.V98.3.814","volume":"98","author":"AR Pettitt","year":"2001","unstructured":"Pettitt AR, Sherrington PD, Stewart G et al (2001) p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation. Blood 98:814\u2013822","journal-title":"Blood"},{"key":"1125_CR6","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1158\/1078-0432.CCR-08-1630","volume":"15","author":"D Rossi","year":"2009","unstructured":"Rossi D, Cerri M, Deambrogi C et al (2009) The prognosis value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13. Clin Cancer Res 15:995\u20131004","journal-title":"Clin Cancer Res"},{"key":"1125_CR7","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","volume":"103","author":"G Lozanski","year":"2004","unstructured":"Lozanski G, Heerema NA, Flinn IW et al (2004) Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103:3278\u20133281","journal-title":"Blood"},{"key":"1125_CR8","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1200\/JCO.2005.03.7184","volume":"24","author":"A Krober","year":"2006","unstructured":"Krober A, Bloehdorn J, Hafner S et al (2006) Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 24:969\u2013975","journal-title":"J Clin Oncol"},{"key":"1125_CR9","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D et al (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines. Blood 111:5446\u20135456","journal-title":"Blood"},{"key":"1125_CR10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/leu.2008.274","volume":"23","author":"F Dicker","year":"2009","unstructured":"Dicker F, Herholz H, Schnittger S et al (2009) The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 23:117\u2013124","journal-title":"Leukemia"},{"key":"1125_CR11","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1182\/blood-2009-05-224071","volume":"114","author":"T Zenz","year":"2009","unstructured":"Zenz T, Habe S, Denzel T et al (2009) Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53\u2013p21 dysfunction, and miR34a in a prospective clinical trial. Blood 114:2589\u20132597","journal-title":"Blood"},{"key":"1125_CR12","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","volume":"28","author":"T Zenz","year":"2010","unstructured":"Zenz T, Eichhorst B, Busch R et al (2010) TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol 28:4473\u20134479","journal-title":"J Clin Oncol"},{"key":"1125_CR13","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2005-05-2093","volume":"107","author":"C Mayr","year":"2006","unstructured":"Mayr C, Speicher MR, Kofler DM et al (2006) Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 107:742\u2013751","journal-title":"Blood"},{"key":"1125_CR14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/sj.thj.6200325","volume":"5","author":"PD Thornton","year":"2004","unstructured":"Thornton PD, Gruszka-Westwood AM, Hamoudi RA et al (2004) Characterisation of TP53 abnormalities in chronic lymphocytic leukaemia. Hematol J 5:47\u201354","journal-title":"Hematol J"},{"key":"1125_CR15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2006.08.3089","volume":"25","author":"MR Grever","year":"2007","unstructured":"Grever MR, Lucas DM, Dewald GW et al (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. J Clin Oncol 25:799\u2013804","journal-title":"J Clin Oncol"},{"key":"1125_CR16","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2008-04-154070","volume":"112","author":"T Zenz","year":"2008","unstructured":"Zenz T, Krober A, Scherer K et al (2008) Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112:3322\u20133329","journal-title":"Blood"},{"key":"1125_CR17","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.beha.2007.03.005","volume":"20","author":"MR Grever","year":"2007","unstructured":"Grever MR, Lucas DM, Johnson AJ, Byrd JC (2007) Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol 20:545\u2013556","journal-title":"Best Pract Res Clin Haematol"},{"key":"1125_CR18","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/sj.leu.2405092","volume":"22","author":"OG Best","year":"2008","unstructured":"Best OG, Gardiner AC, Majid A et al (2008) A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 22:1456\u20131459","journal-title":"Leukemia"},{"key":"1125_CR19","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.cdd.4401194","volume":"10","author":"I Sturm","year":"2003","unstructured":"Sturm I, Bosanquet AG, Hermann S et al (2003) Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 10:477\u2013484","journal-title":"Cell Death Differ"},{"key":"1125_CR20","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","volume":"28","author":"A Petitjean","year":"2007","unstructured":"Petitjean A, Mathe E, Kato S et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622\u2013629","journal-title":"Hum Mutat"},{"key":"1125_CR21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/1078-0432.CCR-05-0413","volume":"12","author":"T Soussi","year":"2006","unstructured":"Soussi T, Asselain B, Hamroun D et al (2006) Meta-analysis of the p53 mutation database for mutant p53 biological activity reveals a methodologic bias in mutation detection. Clin Cancer Res 12:62\u201369","journal-title":"Clin Cancer Res"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-1125-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-010-1125-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-010-1125-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T09:50:16Z","timestamp":1559037016000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-010-1125-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,27]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1007\/s00277-010-1125-8","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,27]]}}}